Gufic Biosciences Limited has submitted its quarterly compliance certificate to the stock exchanges under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory certificate with both BSE and NSE on April 07, 2026.

Regulatory Compliance Filing

The certificate was submitted pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. Company Secretary and Compliance Officer Ami Shah signed the filing on behalf of Gufic Biosciences Limited.

Registrar Confirmation

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's Registrar and Share Transfer Agent. Ashok Shetty, Sr. Vice President-Corporate Registry, signed the confirmation on April 06, 2026.

The registrar confirmed that securities received from depository participants for dematerialisation during Q4 FY26 were processed according to prescribed timelines and regulatory requirements.

Quarter Activity Summary

A notable aspect of this filing is that no dematerialisation requests were received from shareholders during the quarter ended March 31, 2026. The registrar specifically noted this in their confirmation certificate.

Corporate Information

Gufic Biosciences Limited operates from its corporate office at SM House, Sahakar Road, Vile Parle (East), Mumbai, with its registered office located in Andheri (East), Mumbai. The company maintains manufacturing facilities across multiple states including Gujarat, Madhya Pradesh, and Karnataka.

This routine compliance filing demonstrates the company's adherence to SEBI regulations governing depositories and participant operations, ensuring transparency in share transfer and dematerialisation processes.

Gufic biosciences Limited has received a penalty demand of Rs 23,52,396 from the Income Tax Department for Assessment Year 2023-24, according to a regulatory filing made on April 03, 2026. The penalty has been levied under Section 270A(9) of the Income Tax Act on account of alleged under-reported income.

Background of Tax Assessment

The penalty stems from an assessment order received under Section 143(3) read with Section 144B of the Income Tax Act, 1961 for Assessment Year 2023-24. Initially, the company faced a substantial tax demand aggregating to Rs 11,88,88,580. However, following an appeal before the appropriate appellate authority, this demand was significantly reduced to Rs 11,76,198.

Penalty Details and Timeline

Company's Response Strategy

Gufic Biosciences is currently evaluating the penalty order and intends to file an appeal before the Commissioner of Income Tax (Appeals) within the prescribed time limit. The company has stated that based on its assessment, prevailing law, and advice from tax advisors, it remains hopeful of a favorable outcome at the appellate authority level.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This intimation follows previous communications dated April 14, 2025, and March 19, 2025, regarding related tax matters. The company has fulfilled its obligation to inform both BSE Limited and National Stock Exchange of India Limited about this development.

Financial Impact Assessment

Considering the merits of the case and based on professional tax advice, the pharmaceutical company believes it has strong grounds for appeal. The company's confidence in achieving a favorable outcome suggests it does not expect the penalty to have a material adverse impact on its financial position, pending the resolution of the appellate process.